Following a barrage of letters from President Donald Trump urging 17 large pharmaceutical companies to implement Most Favored ...

Genmab and AbbVie are taking key steps toward moving their blood cancer drug Epkinly into earlier lines of treatment in ...

Sanofi is pulling its PCSK9 drug Praluent from the Chinese market. President Donald Trump said U.S. pharmaceutical tariffs may eventually reach 250%. | Sanofi is pulling its PCSK9 drug Praluent from ...

Contract Development and Manufacturing Organizations (CDMOs) have carved out a lucrative niche within the biopharma industry, ...

In line with the Trump administration’s goal to curb the United States’ reliance on overseas drug manufacturing, the FDA has ...

Otte took on the title in February, the culmination of nearly 25 years spent with the Danish drugmaker. As of his departure ...

Lilly has been chasing—and gaining on—its chief metabolic medicine rival Novo Nordisk and its counterpart GLP-1s Ozempic and ...

CorMedix projects Melinta products will generate between $125 million and $135 million in revenue this year. The company also ...

Merck pulled off its $10 billion buyout of Verona Pharma last month with little of the wheeling and dealing that typically ...

Garonit Pharmaceutical, an India-based API maker, plans to build a $46.1 million production plant in New York to produce ...

Vor Bio has handed Dallan Murray a swift return to the workforce. | Vor Bio has handed Dallan Murray a swift return to the ...

After a second Elevidys patient death from acute liver failure, Sarepta in July launched a major restructuring that involves ...